Login / Signup

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis.

Xiaozheng XuPreston DennettJibin ZhangAlice SherrardYunlong ZhaoTakeya MasubuchiJack D BuiXu ChenEnfu Hui
Published in: The Journal of experimental medicine (2023)
CD28 and CTLA4 are T cell coreceptors that competitively engage B7 ligands CD80 and CD86 to control adaptive immune responses. While the role of CTLA4 in restraining CD28 costimulatory signaling is well-established, the mechanism has remained unclear. Here, we report that human T cells acquire antigen-presenting-cell (APC)-derived B7 ligands and major histocompatibility complex (MHC) via trogocytosis through CD28:B7 binding. Acquired MHC and B7 enabled T cells to autostimulate, and this process was limited cell-intrinsically by CTLA4, which depletes B7 ligands trogocytosed or endogenously expressed by T cells through cis-endocytosis. Extending this model to the previously proposed extrinsic function of CTLA4 in human regulatory T cells (Treg), we show that blockade of either CD28 or CTLA4 attenuates Treg-mediated depletion of APC B7, indicating that trogocytosis and CTLA4-mediated cis-endocytosis work together to deplete B7 from APCs. Our study establishes CTLA4 as a cell-intrinsic molecular sink that limits B7 availability on the surface of T cells, with implications for CTLA4-targeted therapy.
Keyphrases
  • regulatory t cells
  • single cell
  • nk cells
  • immune response
  • cell therapy
  • dendritic cells
  • inflammatory response
  • induced pluripotent stem cells
  • case report
  • transcription factor
  • mesenchymal stem cells